215 related articles for article (PubMed ID: 32032705)
21. Pharmacogenomic data: FDA voluntary and required submission guidance.
Salerno RA; Lesko LJ
Pharmacogenomics; 2004 Jul; 5(5):503-5. PubMed ID: 15212586
[No Abstract] [Full Text] [Related]
22. An Evidence-Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized Medicine.
Whirl-Carrillo M; Huddart R; Gong L; Sangkuhl K; Thorn CF; Whaley R; Klein TE
Clin Pharmacol Ther; 2021 Sep; 110(3):563-572. PubMed ID: 34216021
[TBL] [Abstract][Full Text] [Related]
23. Ontogeny and the Application of Pharmacogenomics to Pediatric Drug Development.
Green D
J Clin Pharmacol; 2019 Sep; 59 Suppl 1():S82-S86. PubMed ID: 31502695
[TBL] [Abstract][Full Text] [Related]
24. Characterization of Pharmacogenetic Information in Food and Drug Administration Drug Labeling and the Table of Pharmacogenetic Associations.
Cheng CM; So TW; Bubp JL
Ann Pharmacother; 2021 Oct; 55(10):1185-1194. PubMed ID: 33384014
[TBL] [Abstract][Full Text] [Related]
25. Comparison of FDA Table of Pharmacogenetic Associations and Clinical Pharmacogenetics Implementation Consortium guidelines.
Pritchard D; Patel JN; Stephens LE; McLeod HL
Am J Health Syst Pharm; 2022 Jun; 79(12):993-1005. PubMed ID: 35230418
[TBL] [Abstract][Full Text] [Related]
26. A Review of Patient-Reported Outcomes Labeling for Oncology Drugs Approved by the FDA and the EMA (2012-2016).
Gnanasakthy A; Barrett A; Evans E; D'Alessio D; Romano CD
Value Health; 2019 Feb; 22(2):203-209. PubMed ID: 30711065
[TBL] [Abstract][Full Text] [Related]
27. Differences in pharmacogenomic biomarker information in package inserts from the United States, the United Kingdom and Japan.
Shimazawa R; Ikeda M
J Clin Pharm Ther; 2013 Dec; 38(6):468-75. PubMed ID: 23895776
[TBL] [Abstract][Full Text] [Related]
28. Pediatric drug information available at the time of new drug approvals: A cross-sectional analysis.
Hudgins JD; Bacho MA; Olsen KL; Bourgeois FT
Pharmacoepidemiol Drug Saf; 2018 Feb; 27(2):161-167. PubMed ID: 29148107
[TBL] [Abstract][Full Text] [Related]
29. Rates of genetic testing in patients prescribed drugs with pharmacogenomic information in FDA-approved labeling.
Young J; Bhattacharya K; Ramachandran S; Lee A; Bentley JP
Pharmacogenomics J; 2021 Jun; 21(3):318-325. PubMed ID: 33589791
[TBL] [Abstract][Full Text] [Related]
30. Unraveling heterogeneity of the clinical pharmacogenomic guidelines in oncology practice among major regulatory bodies.
Nagy M; Attya M; Patrinos GP
Pharmacogenomics; 2020 Nov; 21(17):1247-1264. PubMed ID: 33124490
[TBL] [Abstract][Full Text] [Related]
31. Personalized medicine: is it a pharmacogenetic mirage?
Shah RR; Shah DR
Br J Clin Pharmacol; 2012 Oct; 74(4):698-721. PubMed ID: 22591598
[TBL] [Abstract][Full Text] [Related]
32. Accelerating evidence gathering and approval of precision medicine therapies: the FDA takes aim at rare mutations.
Issa AM; Thorogood A; Joly Y; Knoppers BM
Genet Med; 2019 Mar; 21(3):542-544. PubMed ID: 29988078
[No Abstract] [Full Text] [Related]
33. Variability of Pharmacogenomics Information in Drug Labels Approved by Different Agencies and its Ethical Implications.
Güner MD; Ekmekci PE; Kurtoglu B
Curr Drug Saf; 2022; 17(1):47-53. PubMed ID: 34315387
[TBL] [Abstract][Full Text] [Related]
34. Stoning a dead bird: advertising limits on approved new drugs.
Strobos J
Food Drug Law J; 1995; 50(4):533-51. PubMed ID: 10343018
[No Abstract] [Full Text] [Related]
35. Personalized medicine and rescuing "unsafe" drugs with pharmacogenomics: a regulatory perspective.
Avery M
Food Drug Law J; 2010; 65(1):37-65, i-ii. PubMed ID: 24475534
[TBL] [Abstract][Full Text] [Related]
36. Pharmacogenomic information in the Warning section of drug labels: A comparison between labels in the United States and those in five other countries/regions.
Imatoh T; Sai K; Saito Y
J Clin Pharm Ther; 2018 Aug; 43(4):493-499. PubMed ID: 29682780
[TBL] [Abstract][Full Text] [Related]
37. Pharmacogenomics - a minor rather than major force in clinical medicine.
Polasek TM
Expert Rev Clin Pharmacol; 2024 Mar; 17(3):203-212. PubMed ID: 38307498
[TBL] [Abstract][Full Text] [Related]
38. Pharmacogenomics in the assessment of therapeutic risks versus benefits: inside the United States Food and Drug Administration.
Zineh I; Pacanowski MA
Pharmacotherapy; 2011 Aug; 31(8):729-35. PubMed ID: 21923598
[TBL] [Abstract][Full Text] [Related]
39. Evidence for Treatment-by-Biomarker interaction for FDA-approved Oncology Drugs with Required Pharmacogenomic Biomarker Testing.
Vivot A; Boutron I; Béraud-Chaulet G; Zeitoun JD; Ravaud P; Porcher R
Sci Rep; 2017 Jul; 7(1):6882. PubMed ID: 28761069
[TBL] [Abstract][Full Text] [Related]
40. Pharmacogenomics: history, barriers, and regulatory solutions.
Blankstein S
Food Drug Law J; 2014; 69(2):273-314, ii. PubMed ID: 25163212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
